VulnerabilityModified

CVE-2007-6763

SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.

HIGH 8.8EPSS 1.32%

Does this matter?

High impact if exploited, but EPSS currently rates exploitation as unlikely (1.32%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.

Description

SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.

CVSS 3.0: 8.8 HIGHCVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
EPSS: 1.32% probability · 69th percentile
CISA KEV: Not listed
Weakness: CWE-20
Affected: sas/sas drug development
Source: cve@mitre.org

References

http://ftp.sas.com/techsup/download/hotfix/drugdev/32drg02/SDD_Release_Notes_32DRG02.pdfVendor Advisory
http://ftp.sas.com/techsup/download/hotfix/drugdev/32drg02/SDD_Release_Notes_32DRG02.pdfVendor Advisory

Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.